BofA raised the firm’s price target on Intra-Cellular to $82 from $74 and keeps a Buy rating on the shares. The analyst addd one year to Caplyta’s loss of exclusivity runway to give credit for its longer dated patents. The firm says Caplyta is positioned to continue to deliver growth in bipolar depression indication with multiple 2024 opportunities to expand the drug’s label.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ITCI:
- Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Intra-Cellular rumor highlighted in Betaville blog
- Nike upgraded, Paramount downgraded: Wall Street’s top analyst calls
- Intra-Cellular initiated with bullish view at TD Cowen, here’s why
- Intra-Cellular highlights data presentations at ACNP annual meeting